253 related articles for article (PubMed ID: 15724236)
21. Effects of nateglinide on myocardial microvascular reactivity in Type 2 diabetes mellitus--a randomized study using positron emission tomography.
Bengel FM; Abletshauser C; Neverve J; Schnell O; Nekolla SG; Standl E; Schwaiger M
Diabet Med; 2005 Feb; 22(2):158-63. PubMed ID: 15660732
[TBL] [Abstract][Full Text] [Related]
22. Differential therapeutic effects of nateglinide and acarbose on fasting and postprandial lipid profiles: a randomized trial.
Zhou J; Deng Z; Lu J; Li H; Zhang X; Peng Y; Mo Y; Bao Y; Jia W
Diabetes Technol Ther; 2015 Apr; 17(4):229-34. PubMed ID: 25781235
[TBL] [Abstract][Full Text] [Related]
23. Additive hypoglycaemic effect of nateglinide and exogenous glucagon-like peptide-1 in type 2 diabetes.
Bell PM; Cuthbertson J; Patterson S; O'Harte FP
Diabetes Res Clin Pract; 2011 Mar; 91(3):e68-70. PubMed ID: 21194775
[TBL] [Abstract][Full Text] [Related]
24. Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion.
Raz I; Weiss R; Yegorchikov Y; Bitton G; Nagar R; Pesach B
Clin Ther; 2009 May; 31(5):980-7. PubMed ID: 19539098
[TBL] [Abstract][Full Text] [Related]
25. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients.
Miyazaki Y; DeFronzo RA
Diabetes Obes Metab; 2008 Dec; 10(12):1204-11. PubMed ID: 18476983
[TBL] [Abstract][Full Text] [Related]
26. Effects of thorough mastication on postprandial plasma glucose concentrations in nonobese Japanese subjects.
Suzuki H; Fukushima M; Okamoto S; Takahashi O; Shimbo T; Kurose T; Yamada Y; Inagaki N; Seino Y; Fukui T
Metabolism; 2005 Dec; 54(12):1593-9. PubMed ID: 16311091
[TBL] [Abstract][Full Text] [Related]
27. Hepatic fat content is a determinant of postprandial triglyceride levels in type 2 diabetes mellitus patients with normal fasting triglyceride.
Nimitphong H; Phongkitkarun S; Rattarasarn C; Kongsooksai A; Chanprasertyothin S; Bunnag PA; Puavilai G
Metabolism; 2008 May; 57(5):644-9. PubMed ID: 18442627
[TBL] [Abstract][Full Text] [Related]
28. Effects of timing of administration and meal composition on the pharmacokinetic and pharmacodynamic characteristics of the short-acting oral hypoglycemic agent nateglinide in healthy subjects.
Luzio SD; Anderson DM; Owens DR
J Clin Endocrinol Metab; 2001 Oct; 86(10):4874-80. PubMed ID: 11600556
[TBL] [Abstract][Full Text] [Related]
29. Beneficial metabolic effects of nateglinide versus acarbose in patients with newly-diagnosed type 2 diabetes.
Gao HW; Xie C; Wang HN; Lin YJ; Hong TP
Acta Pharmacol Sin; 2007 Apr; 28(4):534-9. PubMed ID: 17376293
[TBL] [Abstract][Full Text] [Related]
30. Real-time assessment of postprandial fat storage in liver and skeletal muscle in health and type 2 diabetes.
Ravikumar B; Carey PE; Snaar JE; Deelchand DK; Cook DB; Neely RD; English PT; Firbank MJ; Morris PG; Taylor R
Am J Physiol Endocrinol Metab; 2005 Apr; 288(4):E789-97. PubMed ID: 15572652
[TBL] [Abstract][Full Text] [Related]
31. Influence of insulin treatment on insulin sensitivity in insulin requiring type 2 diabetes patients.
Mayorov AY; Naumenkova IV; Antsiferov MB; Dedov II
Diabetes Res Clin Pract; 2005 Jun; 68 Suppl1():S54-9. PubMed ID: 15955377
[TBL] [Abstract][Full Text] [Related]
32. Exenatide: effect of injection time on postprandial glucose in patients with Type 2 diabetes.
Linnebjerg H; Kothare PA; Skrivanek Z; de la Peña A; Atkins M; Ernest CS; Trautmann ME
Diabet Med; 2006 Mar; 23(3):240-5. PubMed ID: 16492205
[TBL] [Abstract][Full Text] [Related]
33. Nateglinide improves postprandial hyperglycemia and insulin secretion in renal transplant recipients.
Voytovich MH; Haukereid C; Hjelmesaeth J; Hartmann A; Løvik A; Jenssen T
Clin Transplant; 2007; 21(2):246-51. PubMed ID: 17425753
[TBL] [Abstract][Full Text] [Related]
34. Control of postprandial hyperglycemia: optimal use of short-acting insulin secretagogues.
Carroll MF; Izard A; Riboni K; Burge MR; Schade DS
Diabetes Care; 2002 Dec; 25(12):2147-52. PubMed ID: 12453952
[TBL] [Abstract][Full Text] [Related]
35. [The relationship between insulin resistance and postprandial abnormal serum triglyceride metabolism in essential hypertension].
Lin J; Peng F; Zeng K; Wu K; Kang Q
Zhonghua Yi Xue Za Zhi; 2002 Nov; 82(22):1521-4. PubMed ID: 12609058
[TBL] [Abstract][Full Text] [Related]
36. A single dose of nateglinide improves post-challenge glucose metabolism and endothelial dysfunction in Type 2 diabetic patients.
Shimabukuro M; Higa N; Takasu N; Tagawa T; Ueda S
Diabet Med; 2004 Sep; 21(9):983-6. PubMed ID: 15317602
[TBL] [Abstract][Full Text] [Related]
37. Acarbose lowers serum triglyceride and postprandial chylomicron levels in type 2 diabetes.
Ogawa S; Takeuchi K; Ito S
Diabetes Obes Metab; 2004 Sep; 6(5):384-90. PubMed ID: 15287932
[TBL] [Abstract][Full Text] [Related]
38. Meal testing and postprandial state of type 2 diabetic patients with metabolic syndrome.
Brădescu OM; Georgescu M; Ifrim S; Ioacără S; Ionescu-Tîrgovişte C
Rom J Intern Med; 2005; 43(1-2):97-113. PubMed ID: 16739870
[TBL] [Abstract][Full Text] [Related]
39. Importance of early phase insulin secretion to intravenous glucose tolerance in subjects with type 2 diabetes mellitus.
Kahn SE; Montgomery B; Howell W; Ligueros-Saylan M; Hsu CH; Devineni D; McLeod JF; Horowitz A; Foley JE
J Clin Endocrinol Metab; 2001 Dec; 86(12):5824-9. PubMed ID: 11739446
[TBL] [Abstract][Full Text] [Related]
40. Improved prandial glucose control with lower risk of hypoglycemia with nateglinide than with glibenclamide in patients with maturity-onset diabetes of the young type 3.
Tuomi T; Honkanen EH; Isomaa B; Sarelin L; Groop LC
Diabetes Care; 2006 Feb; 29(2):189-94. PubMed ID: 16443858
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
